Fresenius SE & Co. KGaA · ISIN: DE0005785604 · EQS - adhoc news

Fresenius raises outlook for fiscal year 2024

Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024 Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024. Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (previously: 3 to 6%). Group EBIT at constant currency is now expected to grow between 6 and 10% (previously: 4 to 8%). The increase of the group outlook...

XETR:FRE Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Fresenius SE & Co. KGaA

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (14)
Short Selling (DE) (4)
Short Selling (UK) (0)
07 May 2024 09:19PM
Fresenius raises outlook for fiscal year 2024
DE0005785604
Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024 Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024. Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (pre...
Fresenius SE & Co. KGaA
About the publication
05 December 2023 09:29PM
Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023
DE0005785604
Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023 The Management Board of Fresenius Management SE decided today that Fresenius Group will retain the governmental compensation and reimbursement payments of up to €300 million (from t...
Fresenius SE & Co. KGaA
About the publication
21 February 2023 07:02PM
Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)
DE0005785604
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius ex...
Fresenius SE & Co. KGaA
About the publication
21 February 2023 07:02PM
Fresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)
DE0005785604
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius ex...
Fresenius SE & Co. KGaA
About the publication
09 February 2023 04:24PM
Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation
DE0005785604
As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft). ...
Fresenius SE & Co. KGaA
About the publication
09 February 2023 04:24PM
Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation
DE0005785604
As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft). ...
Fresenius SE & Co. KGaA
About the publication
05 December 2022 11:40PM
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
DE0005785604
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to...
Fresenius SE & Co. KGaA
About the publication
05 December 2022 11:40PM
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
DE0005785604
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to...
Fresenius SE & Co. KGaA
About the publication
30 October 2022 05:36PM
Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
DE0005785604
Fresenius SE & Co. KGaA: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company’s focused efforts to improve North American Health Care...
Fresenius SE & Co. KGaA
About the publication
30 October 2022 05:36PM
Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
DE0005785604
Fresenius SE & Co. KGaA: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company’s focused efforts to improve North American Health Care...
Fresenius SE & Co. KGaA
About the publication
19 August 2022 06:33PM
Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius
DE0005785604
Michael Sen to succeed Stephan Sturm as CEO of Fresenius Michael Sen (53) will become Chief Executive Officer of Fresenius on October 1, 2022. He was appointed unanimously by the Supervisory Board of Fresenius Management SE today to succeed Stephan Sturm (59), who will leave the company on good terms on September 30. Michael Sen will, in addition,...
Fresenius SE & Co. KGaA
About the publication
19 August 2022 06:33PM
Michael Sen to succeed Stephan Sturm as CEO of Fresenius
DE0005785604
Michael Sen to succeed Stephan Sturm as CEO of Fresenius Michael Sen (53) will become Chief Executive Officer of Fresenius on October 1, 2022. He was appointed unanimously by the Supervisory Board of Fresenius Management SE today to succeed Stephan Sturm (59), who will leave the company on good terms on September 30. Michael Sen will, in addition,...
Fresenius SE & Co. KGaA
About the publication
27 July 2022 10:45PM
Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised
DE0005785604
Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised  Fresenius Medical Care’s financial performance in Q2/22 was significantly impacted by worsened labor shortages and related meaningfully increased wage inflation in the U.S. Th...
Fresenius SE & Co. KGaA
About the publication
27 July 2022 10:45PM
Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised
DE0005785604
Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised  Fresenius Medical Care’s financial performance in Q2/22 was significantly impacted by worsened labor shortages and related meaningfully increased wage inflation in the U.S. Th...
Fresenius SE & Co. KGaA
About the publication
More Fresenius SE & Co. KGaA related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 14 4th April 2024 Hennicken, Sara DD
Short Seller (DE) 4 6th November 2024 Ilex Capital Partners (UK) LLP SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN